Clinical Trials for Type 2 Diabetes
225 type 2 diabetes trials indexed, 91 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Type 2 Diabetes
Type 2 diabetes is a chronic condition that affects how the body processes blood sugar, also known as glucose. It occurs when the body either resists the effects of insulin, a hormone that regulates sugar uptake, or does not produce enough insulin to maintain normal glucose levels. This leads to elevated blood sugar, which can damage organs and tissues over time. Doctors diagnose type 2 diabetes using blood tests such as fasting plasma glucose, oral glucose tolerance test, or HbA1c, which measures average blood sugar over the past two to three months. A diagnosis is confirmed when these tests show blood sugar levels above established thresholds.
Common symptoms of type 2 diabetes include increased thirst, frequent urination, fatigue, blurred vision, and slow healing of wounds. The condition often develops gradually and is most commonly diagnosed in adults over 45 years old, although younger people are increasingly affected. Risk factors include excess body weight, physical inactivity, family history of diabetes, and certain ethnic backgrounds such as African American, Hispanic, and Native American. People with prediabetes have higher blood sugar than normal but not high enough for a diabetes diagnosis, placing them at increased risk for developing type 2 diabetes.
Type 2 diabetes is a significant medical and social concern worldwide. It accounts for about 90 to 95 percent of all diagnosed diabetes cases. According to recent estimates, over 34 million people in the United States have diabetes, with type 2 being the most common form. The condition contributes to serious complications like heart disease, kidney failure, and vision loss. Economically, type 2 diabetes costs the U.S. healthcare system more than $300 billion annually, including medical expenses and lost productivity. Managing and preventing this disease is critical due to its widespread impact on health and society.
The Type 2 Diabetes Treatment Landscape
The first-line treatment for type 2 diabetes typically involves lifestyle changes combined with the medication metformin. Lifestyle changes focus on diet, exercise, and weight loss to improve blood sugar control. Metformin works by reducing glucose production in the liver and improving insulin sensitivity. If blood sugar goals are not met with metformin and lifestyle adjustments, additional medications are added in a stepwise manner. Treatment is personalized based on factors like age, kidney function, and other health conditions.
Second- and third-line treatment options include several drug classes. Sulfonylureas stimulate the pancreas to release more insulin. DPP-4 inhibitors help increase insulin release and decrease glucagon levels. SGLT2 inhibitors reduce blood sugar by increasing glucose excretion in urine and have shown benefits for heart and kidney health. GLP-1 receptor agonists enhance insulin secretion and slow gastric emptying. Insulin therapy is often introduced in later stages or when oral medications are insufficient. Each class has specific benefits and side effects, which guide doctors in selecting the best combination for each patient.
Despite many available treatments, gaps remain in managing type 2 diabetes effectively. Some patients experience resistance to certain drugs or cannot tolerate side effects such as gastrointestinal issues or low blood sugar episodes. Others have difficulty achieving long-term glucose control or managing complications. Research is ongoing to develop new therapies that address these challenges, including drugs targeting different biological pathways and personalized medicine approaches. Clinical trials are key to exploring these innovations and improving outcomes for patients who do not respond well to current options.
Why Clinical Trials Matter for Type 2 Diabetes
Clinical trials provide patients with opportunities to access new treatments before they become widely available. These studies offer closer medical monitoring and contribute valuable information to the understanding of type 2 diabetes. Currently, there are 225 type 2 diabetes clinical trials indexed on ClinicalTrials.gov, with 91 actively recruiting participants. Joining a trial allows patients to play a direct role in advancing research that may improve care for themselves and others in the future.
Participation in clinical trials also involves risks. The effectiveness of new treatments is not guaranteed, and some studies include placebo groups that receive no active medication. Additional clinic visits and tests may be required, which can be time-consuming. Side effects from experimental treatments are possible and may be unknown at the start of the trial. Patients should carefully consider these factors and discuss them with their healthcare providers before enrolling in a study.
Sponsors of type 2 diabetes clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. These organizations design and fund trials to test new drugs, devices, or care strategies. ClinicalTrials.gov serves as a comprehensive registry that helps patients, caregivers, and doctors find ongoing studies. It provides detailed information about trial purposes, eligibility criteria, locations, and contact details, making it easier to connect interested individuals with research opportunities.
What to Look for in a Type 2 Diabetes Clinical Trial
Clinical trials are divided into four main phases. Phase 1 tests a new treatment in a small group to evaluate safety and dosage. Phase 2 involves more participants to assess effectiveness and side effects. Phase 3 compares the new treatment to the current standard in larger groups. Phase 4 occurs after approval to monitor long-term effects and safety. For Type 2 Diabetes trials, many do not specify a phase (105 trials). Phase 3 trials are the most common with 25 studies, followed by 18 in Phase 2 and 17 in Phase 4. This distribution shows a focus on testing treatments for effectiveness and safety before wider use.
Inclusion criteria for Type 2 Diabetes trials often focus on specific patient characteristics. Age ranges commonly include adults from 18 to 75 years old, though some trials may focus on older adults. Participants usually must have a diagnosis of Type 2 Diabetes for a certain period, such as at least six months. Prior treatments are often considered; some trials require patients to be on specific medications or not taking others. Biomarkers like blood sugar levels, HbA1c, or insulin resistance tests help determine eligibility. Disease staging and complications may also affect who can join a trial.
Exclusion criteria help protect participants and ensure clear results. Many trials exclude people with other serious health problems, such as heart disease, kidney failure, or liver issues. These comorbidities can affect how the treatment works or increase risks. Drug interactions are a concern, so participants taking certain medications may be excluded. Safety thresholds, like abnormal lab results or uncontrolled blood pressure, often disqualify patients. These rules help keep the trial safe and make sure the results apply to the target group.
Practical considerations are important when deciding to join a trial. The length of a trial can range from a few weeks to several years. Visit schedules vary, with some requiring frequent clinic visits and others fewer. Travel to the research site may be necessary, which can be a challenge for some patients. Before enrolling, ask the research team these questions: How long will the trial last? What tests and procedures will I need? Are there any costs I should expect? What happens if I want to leave the trial early? These questions help patients understand what participation involves and if it fits their lifestyle.
Primary Sources and Further Reading
For those interested in learning more about Type 2 Diabetes and clinical trials, reliable resources can provide detailed and up-to-date information. These sources offer guidance on diabetes management, research updates, and how to find clinical trials. They are maintained by trusted health organizations and government agencies.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Diabetes Overview
- ClinicalTrials.gov - Type 2 Diabetes Trials
- MedlinePlus - Diabetes Information
- Centers for Disease Control and Prevention (CDC) - Diabetes
Latest Research and Emerging Treatments for Type 2 Diabetes (2026)
Several Phase 3 trials are currently testing new drugs that may improve type 2 diabetes treatment. One promising drug is orforglipron, an oral medication studied in multiple trials (NCT06993792, NCT05803421, NCT06972472). Orforglipron works by targeting receptors involved in blood sugar regulation and appetite control. Early data suggests it could help people with type 2 diabetes and obesity manage both blood sugar levels and weight with a simple once-daily pill. This could offer a more convenient alternative to insulin injections for some patients, potentially improving adherence and quality of life.
Another area of research focuses on combination drugs like CagriSema, which combines cagrilintide and semaglutide (NCT06221969). These drugs act on receptors that influence insulin release and appetite, helping to lower blood sugar and reduce body weight. Trials are comparing CagriSema to tirzepatide, a drug already used in type 2 diabetes treatment, to see if it offers additional benefits. For patients, new drugs like these might mean better control of diabetes symptoms and fewer side effects.
Roche is also testing RO7795068, a once-weekly dual GLP-1/GIP receptor agonist (NCT07351058). This drug class helps stimulate insulin production and reduce appetite, which can support weight loss and improve blood sugar control. If successful, RO7795068 could provide another option for people with type 2 diabetes and obesity who need more effective treatment. Ongoing type 2 diabetes research like this aims to expand the choices available, making it easier for patients to find treatments that fit their needs.
Frequently asked questions about Type 2 Diabetes trials
How do I find Type 2 Diabetes clinical trials?
The authoritative source for Type 2 Diabetes clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 225 type 2 diabetes studies are currently indexed. You can search by entering "type 2 diabetes" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new type 2 diabetes trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Type 2 Diabetes trials in?
Across the 225 type 2 diabetes trials TrialsAlert indexes, the most common phase is Phase 3. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Type 2 Diabetes clinical trials are currently recruiting?
As of the latest scan, 91 type 2 diabetes trials have a "Recruiting" status on ClinicalTrials.gov, out of 225 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting type 2 diabetes trial matches their tracked condition.
Stay informed about type 2 diabetes research
Get a weekly briefing with the trials that matter most.